{"created":"2024-11-12T05:06:21.813639+00:00","id":2000013,"links":{},"metadata":{"_buckets":{"deposit":"b1c6d5ee-8f4d-4ac8-b82c-27791a39775e"},"_deposit":{"created_by":8,"id":"2000013","owners":[8],"pid":{"revision_id":0,"type":"depid","value":"2000013"},"status":"published"},"_oai":{"id":"oai:fmu.repo.nii.ac.jp:02000013","sets":["1623632832836:1730783669761"]},"author_link":[],"item_1617186331708":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_title":"Soluble Receptor for Advanced Glycation End Products (RAGE) is a Prognostic Factor for Heart Failure","subitem_title_language":"en"}]},"item_1617186419668":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Koyama, Yo","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Takeishi, Yasuchika","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Niizeki, Takeshi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Suzuki, Satoshi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kitahara, Tatsuro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Sasaki, Toshiki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kubota, Isao","creatorNameLang":"en"}]}]},"item_1617186499011":{"attribute_name":"Rights","attribute_value_mlt":[{"subitem_rights":"Copyright © 2008 Elsevier Inc. All rights reserved.","subitem_rights_language":"en"}]},"item_1617186609386":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_subject":"advanced glycation end products (AGE)","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"receptor for AGE (RAGE)","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"soluble RAGE","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Aged","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Biological Markers","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Disease Progression","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Female","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Glycosylation End Products, Advanced","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Health Status Indicators","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Heart Failure","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Humans","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Male","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Prognosis","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Prospective Studies","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"ROC Curve","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Risk Assessment","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Severity of Illness Index","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"},{"subitem_subject":"Stroke Volume","subitem_subject_language":"en","subitem_subject_scheme":"MeSH"}]},"item_1617186626617":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"Background: We recently reported that serum levels of pentosidine, one of the well defined advanced glycation end products (AGE), was an independent prognostic factor for heart failure. Receptor for AGEs (RAGE) is expressed in a variety of tissues, and RAGE has a C-truncated secretory isoform of the receptor protein, termed soluble RAGE. In the present study, we measured serum soluble RAGE levels in patients and examined whether serum soluble RAGE predicts prognosis in patients with heart failure. Methods and Results: Serum soluble RAGE concentration was measured in 160 patients with heart failure by a competitive enzyme-linked immunosorbent assay. Patients were prospectively followed during a median follow-up period of 872 days with endpoints of cardiac death or re-hospitalization. Serum soluble RAGE level increased with advancing NYHA functional class. Serum soluble RAGE level was also higher in patients with cardiac events than in event free patients. From the receiver operating characteristic (ROC) curve analysis, the cut-off value of serum soluble RAGE level was determined as 1220 pg/ml. Kaplan-Meier analysis clearly demonstrated that the high soluble RAGE group had a significantly higher incidence of cardiac events than occurred in the low serum soluble RAGE group (P = 0.0004). In the multivariate Cox proportional hazard analysis, soluble RAGE and serum pentosidine were independent risk factors for cardiac events (soluble RAGE: HR 1.90, 95% CI 1.16 . 3.09, P = 0.010; pentosidine: HR 1.59, 95% CI 1.11 . 2.29, P = 0.012). Conclusions: Serum soluble RAGE level is an independent prognostic factor for heart failure, and this novel marker may be useful for risk stratification of patients with heart failure.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_1617186643794":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_publisher":"Elsevier Inc.","subitem_publisher_language":"en"}]},"item_1617186702042":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_1617186920753":{"attribute_name":"Source Identifier","attribute_value_mlt":[{"subitem_source_identifier":"1071-9164","subitem_source_identifier_type":"PISSN"},{"subitem_source_identifier":"1532-8414","subitem_source_identifier_type":"EISSN"},{"subitem_source_identifier":"AA11054062","subitem_source_identifier_type":"NCID"}]},"item_1617187056579":{"attribute_name":"Bibliographic Information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2008-03","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"139","bibliographicPageStart":"133","bibliographicVolumeNumber":"14","bibliographic_titles":[{"bibliographic_title":"Journal of Cardiac Failure","bibliographic_titleLang":"en"}]}]},"item_1617258105262":{"attribute_name":"Resource Type","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_1617265215918":{"attribute_name":"Version Type","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_1617353299429":{"attribute_name":"Relation","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1016/j.cardfail.2007.10.019","subitem_relation_type_select":"DOI"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"18325460","subitem_relation_type_select":"PMID"}}]},"item_1617605131499":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2010-06-08"}],"displaytype":"detail","filename":"JCardFail_14_133.pdf","filesize":[{"value":"567.9 KB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"url":"https://fmu.repo.nii.ac.jp/record/2000013/files/JCardFail_14_133.pdf"},"version_id":"861c84ed-1554-4e52-8add-09d2cb7b3849"}]},"item_title":"Soluble Receptor for Advanced Glycation End Products (RAGE) is a Prognostic Factor for Heart Failure","item_type_id":"40002","owner":"8","path":["1730783669761"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2010-06-08"},"publish_date":"2010-06-08","publish_status":"0","recid":"2000013","relation_version_is_last":true,"title":["Soluble Receptor for Advanced Glycation End Products (RAGE) is a Prognostic Factor for Heart Failure"],"weko_creator_id":"8","weko_shared_id":-1},"updated":"2025-01-07T06:27:02.855871+00:00"}